Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial
Journal of Antimicrobial Chemotherapy · 02.04.2025 · 80 (4) · 1141-1147
DOI: 10.1093/jac/dkaf049 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 25.02.2025. Verfasst von Benjamin P Sullivan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Adenine, HIV Infections, Dried Blood Spot Testing, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI, NIGMS, NICHD.
Abstract (Originalsprache)
Background
Tenofovir diphosphate concentration in red blood cells is an objective measure of long-term oral pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) adherence. However, current methods for measuring tenofovir diphosphate are equipment and capital intensive, limiting widespread adoption.
Objectives
Low cost, rapid diagnostics for measuring tenofovir diphosphate may drive clinical adoption of routine drug level measurement as a tool for adherence monitoring of tenofovir disoproxil fumarate-based PrEP or ART. We validate a simple and accessible enzymatic assay [REverSe TRanscrIptase Chain Termination (RESTRICT)] for measuring tenofovir diphosphate in dried blood spots (DBS) obtained from a directly observed therapy study of individuals on PrEP.
Methods
We performed RESTRICT measurements on 74 DBS samples from individuals on tenofovir disoproxil fumarate/emtricitabine regimens. We compared RESTRICT measurements with those from a gold-standard method of liquid chromatography tandem mass spectrometry (LC-MS/MS). The ability of RESTRICT to correctly classify DBS tenofovir diphosphate concentrations to established steady-state adherence benchmark concentrations was determined using area under receiver operating characteristic curves (AUCs).
Results
The RESTRICT measurements of DBS samples were highly correlated with LC-MS/MS measurements of tenofovir diphosphate from DBS (r = −0.90; P < 0.0001). The RESTRICT assay correctly classified DBS samples as above or below established steady-state adherence benchmark concentrations corresponding to low (AUC = 0.974), moderate (AUC = 0.936) and high (AUC = 0.955) levels of adherence.
Conclusions
The enzymatic RESTRICT assay can accurately measure tenofovir diphosphate concentrations in DBS specimens using simple procedures and readily available laboratory equipment, offering accessible objective adherence monitoring for persons receiving tenofovir disoproxil fumarate-based PrEP or ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Mechanical Engineering, University of Washington, Seattle, WA, USA.
- Department of Bioengineering, University of Washington, Seattle, WA, USA.
- Department of Medicine, Sanpatong Hospital, Chiang Mai, Thailand.
- AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
- Department of Epidemiology, University of Washington, Seattle, WA, USA.
- Department of Global Health, University of Washington, Seattle, WA, USA.
ORCID-Profile: Paul K Drain, Jonathan D Posner
Förderung
- NHLBI
- NIGMS
- NICHD
- NIAID NIH HHS
- NIAID
- University of Washington/Fred Hutch Center
- NCI
- NIA
Zitieren
APA
Sullivan, B. P., Craig, C. A., Bender, A. T., Blake, E., Siriprakaisil, O., Sukrakanchana, P. O., Cressey, T. R., Drain, P. K., Olanrewaju, A. O., & Posner, J. D. (2025). Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial. Journal of Antimicrobial Chemotherapy, 80(4), 1141-1147. https://doi.org/10.1093/jac/dkaf049
Vancouver
Sullivan BP, Craig CA, Bender AT, Blake E, Siriprakaisil O, Sukrakanchana PO, et al. Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial. Journal of Antimicrobial Chemotherapy. 2025;80(4):1141-1147. doi:10.1093/jac/dkaf049
BibTeX
@article{Sullivan2025,
author = {Sullivan, Benjamin P and Craig, Cosette A and Bender, Andrew T and Blake, Emily and Siriprakaisil, Oraphan and Sukrakanchana, Pra-Ornsuda and Cressey, Tim R and Drain, Paul K and Olanrewaju, Ayokunle O and Posner, Jonathan D},
title = {Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trial},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {4},
pages = {1141--1147},
doi = {10.1093/jac/dkaf049}
}
EUVIMED